Key points are not available for this paper at this time.
There are still too few large-scale comparative studies. For future trials, we recommend to assess comorbidities, quality of life, symptoms and signs with standardized tools and attempt to better define responder profiles to specific drug treatments.
Attal et al. (Wed,) studied this question.